<DOC>
	<DOCNO>NCT02082249</DOCNO>
	<brief_summary>This extension study evaluate long-term safety tolerability ABT-SLV187 subject advance Parkinson 's disease .</brief_summary>
	<brief_title>An Extension Study Assess Safety , Tolerability Efficacy ABT-SLV187 Subjects With Advanced Parkinson 's Disease Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Antiparkinson Agents</mesh_term>
	<criteria>1 . Subjects complete 12 week treatment Study M12921 would benefit longterm treatment ABTSLV187 . Alternatively , subject ( ) participate Phase 2 Study M12925 ( ii ) would , opinion Investigator , benefit ABTSLV187 treatment Study M12923 , ( iii ) discontinue M12925 Study due safety reason , ( iv ) meet entry requirement . 2 . The subject must able understand nature study must provide write informed consent prior conduct study procedure ( include change occur subject 's current therapeutic regimen ) . 3 . The subject must willing continue treatment . 1 . Subject enrol another clinical trial . 2 . Psychiatric , neurological behavioral disorder may interfere ability subject give informed consent , interfere conduct study . 3 . Medical , laboratory , surgical issue deem Investigator clinically significant opinion PI , would contraindication continued levodopa therapy . 4 . Uncooperative attitude reasonable likelihood noncompliance protocol . 5 . Subject current significant suicidal ideation evidence answer `` yes '' question 4 5 suicidal ideation portion ColumbiaSuicide Severity Rating Scale complete Week 12 Visit Study M12921 Baseline Visit current study M12925 study subject . 6 . Consideration Investigator , reason , subject unsuitable candidate continue receive ABTSLV187 .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>carbidopa</keyword>
	<keyword>Tolerability</keyword>
	<keyword>levodopa</keyword>
	<keyword>levodopa-carbidopa intestinal gel</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Advanced Parkinson 's Disease</keyword>
	<keyword>Safety</keyword>
</DOC>